Metastatic Calcinosis Cutis Associated With a Selective FGFR Inhibitor

JAMA Dermatol. 2019 Jan 1;155(1):122-123. doi: 10.1001/jamadermatol.2018.4070.

Authors

David R Carr¹, Llana Pootrakul¹, Hui-Zi Chen², Catherine G Chung^{1

3}

Affiliations

¹ Division of Dermatology, Department of Medicine, The Ohio State University, Columbus.
² Division of Medical Oncology, Department of Medicine, The Ohio State University, Columbus.
³ Division of Dermatopathology, Department of Pathology, The Ohio State University, Columbus.

PMID: 30476938
DOI: 10.1001/jamadermatol.2018.4070

No abstract available

Publication types

Case Reports

MeSH terms

Antineoplastic Agents / therapeutic use
Bile Duct Neoplasms / diagnosis*
Bile Ducts, Intrahepatic*
Biopsy
Calcinosis / diagnosis
Calcinosis / drug therapy*
Calcinosis / etiology
Cholangiocarcinoma / diagnosis
Cholangiocarcinoma / secondary*
Diagnosis, Differential
Humans
Imidazoles / therapeutic use*
Male
Middle Aged
Pyridazines / therapeutic use*
Receptors, Fibroblast Growth Factor / antagonists & inhibitors*
Skin / pathology
Skin Diseases / diagnosis
Skin Diseases / drug therapy*
Skin Diseases / etiology
Skin Neoplasms / complications
Skin Neoplasms / diagnosis
Skin Neoplasms / secondary

Substances

Antineoplastic Agents
Imidazoles
Pyridazines
Receptors, Fibroblast Growth Factor
ponatinib